Congress Wealth Management LLC DE Buys 19,687 Shares of Pfizer Inc. (NYSE:PFE)

Congress Wealth Management LLC DE boosted its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 48.7% during the 4th quarter, HoldingsChannel reports. The fund owned 60,134 shares of the biopharmaceutical company’s stock after purchasing an additional 19,687 shares during the period. Congress Wealth Management LLC DE’s holdings in Pfizer were worth $1,731,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Carr Financial Group Corp boosted its holdings in shares of Pfizer by 3.3% in the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares during the period. Advisor OS LLC boosted its holdings in shares of Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 365 shares during the period. Safeguard Investment Advisory Group LLC boosted its holdings in shares of Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares during the period. Monetary Management Group Inc. boosted its holdings in shares of Pfizer by 1.0% in the third quarter. Monetary Management Group Inc. now owns 38,651 shares of the biopharmaceutical company’s stock valued at $1,282,000 after purchasing an additional 375 shares during the period. Finally, King Wealth Management Group boosted its holdings in shares of Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 388 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

NYSE PFE opened at $28.88 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock’s fifty day moving average price is $27.27 and its 200 day moving average price is $27.92. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The company has a market cap of $163.65 billion, a price-to-earnings ratio of -481.25, a PEG ratio of 1.13 and a beta of 0.63.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the firm earned $1.23 EPS. The firm’s revenue was down 19.5% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.82%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $35.86.

Check Out Our Latest Stock Analysis on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.